Home
Affibody AB

Affibody AB Market Share Analysis for May 2026

The next generation radiopharmaceuticals Affibody is a biotechnology company developing next generation radiopharmaceuticals based on our proprietary Affibody® platform

Industry: N/A

Domainaffibody.com

Year Founded1998

Employees51 - 200

Annual Revenue$10M - $15M

Affibody AB

Affibody AB (including company regionals)

affibody.com

See more website traffic and engagement information

Affibody AB Revenue up to May 2026 is 10M - 15M

revenue generated by Affibody AB top domains

Affibody AB top domains revenue over 3 years

Revenue for Affibody AB top domains

affibody.com10M - 15M

See more with Sales Intelligence

Total visits to Affibody AB's top domains

Understand Affibody AB market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Affibody AB's top domains

Analyze Affibody AB engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Affibody AB's top domains

See how Affibody AB keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Affibody AB top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Affibody AB

These are the website technologies, by industry, used by Affibody AB top domains

Widget (5)

Twemoji

Advertising (2)

DoubleClick

Content Management System (2)

WordPress

Conversion & Analytics (2)

Google Analytics

More Technologies

9

See all

News & Signals from Affibody AB

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsAffibody AB hired Peter Zerhouni as Chief Business Officer on Apr 1st '23.Affibody appoints Peter Zerhouni as CBO.

NewsAffibody AB is developing innovative treatments for respiratory diseases.Affibody and Chiesi Group have announced the execution of a collaboration and licensing agreement to develop and commercialize innovative treatments for respiratory diseases using Affibody’s technology.

NewsAffibody AB is developing izokibep, an antibody mimetic interleukin-17A inhibitor.The company has entered into an agreement with Swedish biotech Affibody to develop and commercialize izokibep, an antibody mimetic interleukin-17A inhibitor designed to overcome the limitations of monoclonal antibodies.